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Abstract
Higher levels of circulating estrogens and estrogen metabolites (EMs) have been associated with 
higher breast cancer risk. In breast tissues, reduced levels of terminal duct lobular unit (TDLU) 
involution, as reflected by higher numbers of TDLUs and acini per TDLU, have also been linked 
to elevated breast cancer risk. However, it is unknown whether reduced TDLU involution mediates 
the risk associated with circulating EMs. In a cross-sectional analysis of 94 premenopausal and 92 
postmenopausal women referred for clinical breast biopsy at an academic facility in Vermont, we 
examined the associations of 15 EMs, quantified using liquid chromatography-tandem mass 
spectrometry, with number of TDLUs and acini count/TDLU using zero-inflated Poisson 
regression with a robust variance estimator and ordinal logistic regression models, respectively. All 
analyses were stratified by menopausal status and adjusted for potential confounders. Among 
premenopausal women, comparing the highest vs. lowest tertiles, levels of unconjugated estradiol 
(risk ratio [RR]=1.74, 95% confidence interval [CI]=1.06–2.87, p-trend=0.03), 2-hydroxyestrone 
(RR=1.74, 95% CI=1.01–3.01, p-trend=0.04), and 4-hydroxyestrone (RR=1.74, 95% CI=0.99–
3.06, p-trend=0.04) were associated with significantly higher TDLU count. Among 
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postmenopausal women, higher levels of estradiol (RR=2.09, 95% CI=1.01–4.30; p-trend=0.04) 
and 16α-hydroxyestrone (RR=2.27, 95% CI=1.29–3.99, p-trend=0.02) were significantly 
associated with higher TDLU count. Among postmenopausal women, higher levels of EMs, 
specifically conjugated estrone and 2- and 4-pathway catechols, were also associated with higher 
acini count/TDLU. Our data suggest that higher levels of serum EMs are generally associated with 
lower levels of TDLU involution.
Keywords
estrogen; breast tissue; involution; TDLU; sex hormones
INTRODUCTION
High levels of exposure to endogenous estrogens have been shown to increase breast cancer 
risk [1,2]. Pooled analyses of prospective studies have estimated a 1.4-fold higher 
premenopausal breast cancer risk [1] and a 2-fold higher postmenopausal breast cancer risk 
[2] in women with the highest vs. the lowest quintiles of circulating estradiol levels. With 
advances in technology that have allowed reliable measurements of individual estrogen 
metabolites (EMs), recent studies have found similar positive associations between serum 
EMs and postmenopausal breast cancer risk [3–5]. Estrogen metabolites are formed when 
parent estrogens (estrone, estradiol) are hydroxylated at the 2-, 4-, or 16-carbon position of 
the steroid ring and are hypothesized to stimulate cell proliferation largely through estrogen 
receptor (ER)-mediated mechanisms and to damage DNA through producing quinone DNA 
adducts [6–8]. The individual EMs have varying degrees of carcinogenic potential 
depending on their hydroxylation pathway, methylation, and conjugation status [9–11]. For 
example, 2-pathway EMs have been suggested to have lower estrogenic potential as they 
have a faster rate of dissociation from ER than 4-pathway EMs [12]. Methylated catechols of 
2- and 4-pathways are hypothesized to be less genotoxic than catechols as they do not 
undergo further redox cycling [12,13].
Terminal duct lobular units (TDLUs) are the predominant anatomical structures of the breast 
from which breast carcinomas originate [14]. As women age, the numbers of TDLUs and 
acini (epithelial substructures) within TDLUs decrease through a process called TDLU 
involution [15]. Reduced TDLU involution, indicated by higher numbers of TDLUs and 
acini per TDLU, has been associated with higher breast cancer risk among women with 
benign breast disease (BBD) [16–19]. Further, several breast cancer risk factors, including 
hormonally-related factors such as younger age at menarche and fewer years since 
menopause, have been shown to be associated with higher TDLU count among women 
without BBD [20], further supporting evaluation of TDLUs and their epithelial cell content 
as an intermediate endpoint for breast cancer. However, little is known about whether 
circulating EMs, with their proliferative potential, increase breast cancer risk through their 
associations with higher numbers of TDLUs and acini/TDLU in breast tissue.
To the best of our knowledge, no study to date has examined the relationships between 
specific EMs and TDLU involution. One previous study of TDLU involution among women 
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without BBD measured serum estradiol using an immunoassay and reported that elevated 
estradiol levels were associated with higher TDLU count [21]. Herein, we used a high-
performance liquid chromatography-tandem mass spectrometry (LC/MS-MS) assay to refine 
measurements and extended the analysis to examine detailed patterns of estrogen 
metabolism in relation to highly reliable measures of TDLUs and acini count/TDLU in the 
background normal breast tissue from women undergoing diagnostic breast biopsy. We also 
examined whether the associations for specific EMs were independent of unconjugated 
estradiol, the bioactive form of estrogen strongly associated with breast cancer risk.
MATERIALS AND METHODS
Study population
The National Cancer Institute (NCI) Breast Radiology Evaluation and Study of Tissues 
(BREAST) Stamp Project is a cross-sectional molecular epidemiologic study of 
mammographic density conducted among 465 women, aged 40 to 65 years, who were 
referred for diagnostic image-guided breast biopsy from 2007 through 2010 at the University 
of Vermont Medical Center. Details of this study have been previously described [22]. 
Participants had no prior history of breast cancer or cancer treatments, had not undergone 
breast surgery within one year of enrollment, did not have breast implants, and were not 
taking breast cancer chemoprevention. A standard self-administered questionnaire and a 
supplementary telephone interview collected information on participants’ medical history 
and breast cancer risk factors. Height and weight were measured on the day of the breast 
biopsy. Blood samples were voluntarily provided by 324 women (70%) as part of the 
project. Participant characteristics were similar among women who provided blood and 
those who did not. A women was considered postmenopausal if menstrual periods had 
stopped more than 12 months prior to interview, she had undergone bilateral oophorectomy, 
or she had undergone a hysterectomy and was 55 years or older. Among premenopausal 
women, menstrual cycle length and phase were estimated using the date of their last 
menstrual period reported at the time of blood collection and the date of the first day of their 
next menstrual period reported via a postcard returned after the blood collection. Menstrual 
cycle length was determined by computing the difference in days between the self-reported 
date of last menstrual period at the time of blood collection and the first day of the next 
menstrual period following blood collection. Menstrual cycle phase was categorized as 
luteal if blood was collected within the last 11 days of the menstrual cycle and 
perioovulatory if blood was collected 12–16 days before the end of the menstrual cycle; 
otherwise, the participants were considered to be in follicular phase. If menstrual cycle 
length could not be determined due to either a missing or invalid date of last or next 
menstrual period, we assumed a 28-day cycle length and counted either forward (if date of 
last menstrual period was available) or backward (if date of next menstrual period was 
available) and classified as follows: follicular (blood collected on days 1–10 of the menstrual 
cycle), periovulatory (days 11–16), and luteal (days 17–28). Mammographic density was 
measured on the mammogram taken closest in time prior to the breast biopsy date. Volume 
measures of mammographic density were assessed using single X-ray absorptiometry (SXA) 
[23]. Final pathologic diagnoses were obtained from pathology reports.
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Of the 324 women who provided at least one vial of serum, the current analysis excluded 29 
current exogenous hormone users, 19 women with unknown menopausal status, 57 
premenopausal women with indeterminate menstrual cycle phase, and 15 women with ≤3.2 
mL of serum available. We further excluded 13 perimenopausal women (who had menstrual 
periods in the last 12 months but had a serum follicle-stimulating hormone [FSH] level of 
>33.4 IU/L, or whose menstrual periods stopped more than 12 months prior to interview but 
had a FSH level of <23 IU/L and an estradiol level of >37 pg/mL) and five women without 
biopsy tissue available for research. A total of 186 women (94 premenopausal, 92 
postmenopausal) were included in the final analytic population.
Participants provided written informed consent and the study was approved by Institutional 
Review Boards at the University of Vermont and the NCI.
Blood Collection and Laboratory Assays
Blood collection [24] and EM hormone assay [25] methods have been described previously. 
Aliquoted serum vials were stored in liquid nitrogen until their transfer to the Laboratory of 
Proteomics and Analytical Technologies, Cancer Research Technology Program, Leidos 
Biomedical Research, Inc. (Frederick, MD) for testing.
Combined concentrations of conjugated and unconjugated forms of each of 15 individual 
EM (estrone, estradiol, 2-hydroxyestrone, 2-hydroxyestradiol, 2-methoxyestrone, 2-
methoxyestradiol, 2-hydroxyestrone-3-methyl ether, 4-hydroxyestrone, 4-methoxyestrone, 
4-methoxyestradiol, 16a-hydroxyestrone, estriol, 17-epiestriol, 16-ketoestradiol, 16-
epiestriol) and unconjugated concentrations of five EMs (estrogen, estradiol, estriol, 2-
methoyxestrone, 2-methoxyestradiol) in serum were measured in pmol/L using stable 
isotope dilution LC-MS/MS [25]. For those five EMs with both combined and unconjugated 
measurements, their conjugated concentration was estimated by subtracting the 
unconjugated concentration from the combined concentration. EMs were also grouped by 
pathways (e.g., parent estrogens, 2-, 4-, 16-hydroxylation pathways) and pathway ratios 
(e.g., catechols/methylated catechols). “Sum EMs” was also calculated by adding up all 15 
individual EMs. Assay reliability was monitored using 10% masked quality control samples. 
Coefficients of variation were <3%; intraclass correlation coefficients were >99% for each 
EM [24].
Morphometric TDLU assessment
TDLU assessment was performed as described previously [20,26]. Briefly, hematoxylin and 
eosin (H&E) stained sections were digitized at 20× magnification (Aperio ScanScope CS, 
Vista, CA) and evaluated using a web-based system (Digital Image Hub software; SlidePath/
Leica, Dublin, Ireland). A pathologist (MES) evaluated the images to enumerate normal 
TDLUs per section and estimated the percent nonfat tissue area in categories (0, 1, 5, 10, 20, 
30, 40, 50, 60, 70, 80, 90, 95, 99, 100%). The lasso tool in Digital Image Hub was used to 
manually outline and measure total tissue area (mm2) per section. Using this information, 
we computed the number of TDLUs per mm2 of nonfat tissue area (“TDLU count”). Among 
women with observable TDLUs, a semi-automated image analysis tool was used to quantify 
the number of acini per TDLU (“acini count/TDLU”) as previously described [27,21]. For 
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acini count/TDLU, up to 10 TDLUs were reviewed to provide reliable estimates [28] and 
median values were selected as a single summary measure for each woman. Among women 
who had mammographic density measured (92 premenopausal, 88 postmenopausal women), 
we also estimated their total TDLU content in the entire breast (“total TDLU volume”) by 
multiplying the TDLU count per mm2 nonfat tissue area with the summed absolute dense 
volume of both breasts. A previous study [20] demonstrated high intra-observer agreement 
(Spearman r>0.90) with the study pathologist (MES) for the TDLU measures and found 
moderate inverse correlations between these TDLU measures and the qualitative, subjective 
impression of TDLU involution, which had been previously linked to mammographic 
density and breast cancer risk [29].
Statistical analysis
All analyses were stratified by menopausal status, as levels of serum EM [30,24] and TDLU 
measures [20,26] substantially vary by this characteristic. Each EM measure was categorized 
into tertiles (T1, T2, and T3 indicate the first, second, and third tertiles) within pre- and 
postmenopausal women. Zero-inflated Poisson regression (ZIP) [31] models, with a 
sandwich robust variance estimator [32,33], were fit to accommodate the count data with 
excess zeros (zero TDLU count) and to estimate relative risks (RRs) and 95% confidence 
intervals (CIs) for the relationship between serum EM levels and TDLU count. In the ZIP 
models, we standardized the TDLU count by including the nonfat tissue area on the H&E 
slides as an offset. Among women with at least one observable TDLU, ordinal logistic 
regression models were used to estimate odds ratios (ORs) and 95% CIs for the associations 
between EM levels and median acini count/TDLU, categorized in tertiles. We adjusted all 
multivariable models for age and other potential confounders. For each outcome, potential 
confounders (percentage of fat on the H&E slide, body mass index [kg/m2], smoking status, 
age at menarche, first-degree family history of breast cancer, age at first birth/parity, and 
biopsy type) were included in the multivariable models only if they were associated with 
both the exposure and the outcome, assessed separately in pre- and postmenopausal women. 
Since additional adjustment for menstrual phase in premenopausal women and age at 
menopause in postmenopausal women did not change the results, these variables were not 
included in the final models. In a separate model, we additionally adjusted for unconjugated 
estradiol to examine the association of each EM independent of unconjugated estradiol. 
Tests for trend were performed by including exposures in the model as a continuous variable 
(EM tertiles as an ordinal trend).
In secondary analyses, we stratified premenopausal women by their menstrual phase 
(follicular, periovulatory, luteal) because premenopausal hormones levels vary by menstrual 
cycle phase. In addition, postmenopausal women were stratified by the percentage of fat on 
the H&E slides (≥40% vs. <40 %) to assess whether associations differ among women who 
tend to have a higher proportion of breast adipose tissue which may serve as a reservoir of 
hormones and cytokines [34]. All stratified analyses were adjusted only for age due to small 
sample sizes within subgroups. In an additional secondary analysis, we also estimated ORs 
and 95% CIs for the associations between EM levels and total TDLU volume (in quintile 
categories) using ordinal logistic regression models, adjusting for potential confounders. In 
sensitivity analyses, we repeated analyses after excluding women who may have had 
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extreme values of EMs and TDLU measures: women who were diagnosed with breast 
carcinoma (in situ or invasive) at biopsy (n=9 premenopausal, n=22 postmenopausal 
women), current smokers (n=7 premenopausal, n=11 postmenopausal women), and women 
who had used hormones within the prior year (n=6 premenopausal, n=10 postmenopausal 
women).
All statistical tests were two-sided with 5% type I error. Given the correlated exposures 
(r=0.19–0.97 among the 15 EMs) (Supplementary Tables 1–2), we also applied a False 
Discovery Rate (FDR) adjustment for multiple testing (44 tests per outcome) in secondary 
analyses; however, none of the p-values for trend, with the exception of few EMs in 
stratified analysis, remained statistically significant after the adjustment (adjusted p>0.05). 
The ZIP models with the robust variance were estimated using the R software, version 3.2.4, 
and all other analyses were conducted with the SAS software, version 9.3 (SAS Institute 
Inc., Cary, NC).
RESULTS
Study population characteristics
The mean age at biopsy was 45.8 years for premenopausal women (n=94) and 57.2 years for 
postmenopausal women (n=92) (Table 1). Most women were non-Hispanic white (92%), 
parous (76%), and had used oral contraceptives in the past (85%). Compared with 
premenopausal women, postmenopausal women, on average, had lower dense breast 
volume. In addition, postmenopausal women were more likely to have had menarche at age 
≤12 years, to be ever smokers, and to have been diagnosed with in situ or invasive carcinoma 
at breast biopsy. As expected, median TDLU count and median acini count/TDLU were 
higher in premenopausal women than in postmenopausal women (26.1 vs. 11.3 TDLUs per 
100 mm2 nonfat tissue area, and 15.8 vs. 8.0 acini/TDLU). Median serum EM levels for pre- 
and postmenopausal women are presented in Supplementary Table 3. Among 
premenopausal women, median serum EM levels were generally lowest in the follicular 
phase and highest in the periovulatory phase.
Premenopausal women
Among premenopausal women, most individual EMs were generally positively associated 
with TDLU count (Table 2). Specifically, higher levels of unconjugated estradiol 
(RRT3 vs. T1=1.74, 95% CI=1.06–2.87, p-trend=0.03), 2-hydroxyestrone (RRT3 vs. T1=1.74, 
95% CI=1.01–3.01, p-trend=0.04), and 4-hydroxyestrone (RRT3 vs. T1=1.74, 95% CI=0.99–
3.06, p-trend=0.04) were statistically significantly associated with higher TDLU count. 
These associations remained statistically significant after additional adjustment for 
unconjugated estradiol (p-trend=0.03). The ratio of 4-pathway to 16-pathway EMs 
(RRT3 vs. T1=1.92, 95% CI=1.22–3.04, p-tend=0.01) was also significantly associated with 
higher TDLU count independent of unconjugated estradiol.
Although we had limited sample sizes within strata defined by menstrual cycle phase, we 
observed suggestive heterogeneity in associations by menstrual phase for some EMs 
(Supplementary Table 4). Most EMs measured in the follicular phase were positively 
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associated with TDLU count, consistent with findings for all premenopausal women 
combined. However, associations for luteal phase EMs were variable, showing positive 
associations for levels of 2- and 4-pathway catechols only. Periovulatory levels of estriol 
were inversely associated with TDLU count.
Among premenopausal women with observable TDLUs, higher levels of 2-hydroxyestradiol, 
conjugated estriol, and 16-epiestriol were associated with lower acini count/TDLU 
(Supplementary Table 5).
Postmenopausal women
Among postmenopausal women, higher levels of estradiol (RRT3 vs. T1=2.09, 95% CI=1.01–
4.30, p-trend=0.04) and 16α-hydroxyestrone (RRT3 vs. T1=2.27, 95% CI=1.29–3.99, p-
trend=0.02) were significantly associated with higher TDLU count (Table 3). After 
additional adjustment for unconjugated estradiol, these associations remained statistically 
significant, and higher levels of estrone were also significantly associated with higher TDLU 
count (p-trend=0.04).
When we stratified analyses by percent fat on the H&E slides, we observed some 
heterogeneity in associations (Supplementary Table 6). The associations between EMs and 
TDLU count were generally positive among women with <40% fat on the slides. Among 
women with ≥40% fat on the slides, the associations were inverse for most 2- and 4-pathway 
EMs, and 17-epiestriol; however, sample sizes within strata were small.
Among postmenopausal women with observable TDLUs, EMs were generally associated 
with higher acini count/TDLU; the associations were statistically significant for conjugated 
estrone, and 2-pathway and 4-pathways catechols (all p-trend<0.05) (Supplementary Table 
5).
Sensitivity analyses among pre- and postmenopausal women
When we accounted for total mammographic dense volume in order to estimate total TDLU 
volume in the entire breast, individual EMs were generally positively associated with total 
TDLU volume in both pre- and postmenopausal women, but the confidence intervals were 
wider than those observed for the relationships between EMs and TDLU count 
(Supplementary Table 7).
Results were similar when excluding pre- and postmenopausal women who were diagnosed 
with in situ or invasive carcinoma at biopsy, excluding current smokers, or excluding women 
who had used exogenous hormones within the prior year (data not shown).
DISCUSSION
In this cross-sectional study of women undergoing diagnostic image-guided breast biopsy, 
higher levels of serum estradiol were associated with higher TDLU count in both pre- and 
postmenopausal women. Independent of unconjugated estradiol, levels of 2- and 4-pathway 
catechols in premenopausal women and levels of 16α-hydroxyestrone in postmenopausal 
women were also associated with higher TDLU count. Among postmenopausal women, 
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higher levels of parent estrogens and 2- and 4-pathway catechols were associated with 
higher acini count/TDLU. Our findings suggest opportunities for future investigations 
evaluating whether EMs increase breast cancer risk through maintaining higher numbers of 
TDLUs and acini/TDLU in breast tissue.
To our knowledge, this is the first study to evaluate a panel of serum EMs in relation to 
TDLU measures. Among women without BBD, we previously reported that higher levels of 
serum estradiol were associated with higher TDLU count in postmenopausal women and 
premenopausal women in the follicular phase [21]. In the present study of women referred to 
diagnostic breast biopsy, findings were consistent; furthermore, we demonstrated 
associations of specific EMs with TDLU count independent of unconjugated estradiol, the 
bioactive form of estrogen strongly associated with breast cancer risk.
Prior studies of postmenopausal women have consistently found that higher circulating 
levels of parent estrogens are associated with higher breast cancer risk, whereas a higher 
ratio of 2-pathway EMs to parent estrogens is associated with lower risk [4,5,3]. A potential 
underlying mechanism for these associations is that, when EMs bind ER, they facilitate cell 
proliferation and reduce apoptosis [9], thereby maintaining high numbers of TDLUs in 
breasts and elevating breast cancer risk. Compared with 4- or 16-pathway EMs, 2-pathway 
EMs dissociate faster from ER [35] and may be more rapidly cleared from the body than 
parent estrogens [10,11], therefore producing less proliferative stimulus of breast epithelial 
cells. In the present study, although statistically non-significant, we found a similar pattern 
of associations between postmenopausal EMs and TDLU count, lending support to the 
notion that TDLU involution may mediate the effects of EMs on postmenopausal breast 
cancer risk.
In premenopausal women, we observed suggestive heterogeneity in associations between 
EMs and TDLU count by menstrual cycle phase, although interpretation was limited by 
small numbers. As hormones levels fluctuate across the menstrual cycle and the interaction 
of EMs with other hormones (e.g., progesterone) at different times of the menstrual cycle 
may influence the associations, longitudinal studies are needed to confirm the differing 
effects of follicular vs. luteal hormone exposure on breast cancer risk and its intermediate 
endpoints.
Our findings relating serum EMs to TDLU count are consistent with previous studies of 
EMs and mammographic density, which, like TDLU count, is also thought to be an 
intermediate marker of breast cancer risk [36]. Luteal levels of serum estriol and 
postmenopausal levels of serum parent estrogens, 2-, 4-, and 16-pathway EM groups have 
previously been shown to be weakly but positively associated with percent and absolute 
measures of dense area in the same study population [24]. In the studies of urinary EMs and 
mammographic density [37,38], 2-pathway catechols in premenopausal women were 
suggestively positively associated with higher percent mammographic density [37] and the 
ratios of 2-, 4-, and 16-pathway EMs to parent estrogens in postmenopausal women were 
inversely associated with percent and absolute dense area [38]. Previous data suggest that 
TDLU involution is inversely related to mammographic density [39,26], suggesting that 
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further etiologic research incorporating hormone measures with these features of breast 
composition are warranted.
Although measures of TDLU involution and mammographic density are closely related 
[39,26], studies suggest that they are independently associated with breast cancer risk [29]. 
TDLUs are the major epithelial structures of breast where breast cancers arise [14], whereas 
mammographic density reflects stromal and epithelial tissue [40,41]. In the present study, we 
observed significant associations with TDLU count, suggesting that EMs may have a direct 
influence on epithelial tissue and specifically TDLU content.
When evaluating EM associations with total TDLU volume, we generally observed positive 
associations among both pre- and postmenopausal women. In this analysis, using a 
combinatorial metric that incorporated both TDLU number on a biopsy tissue section and 
absolute dense volume from mammography in the outcome calculation contributed to larger 
variances, resulting in wide confidence intervals. Future efforts to more directly study the 
total TDLU count or total epithelial content in the entire breast may give more insight into 
the overall process of TDLU involution and its relationship with breast cancer risk.
As acini count/TDLU is weakly correlated with TDLU count [20,26], TDLU number and 
acinar content may indicate different biological processes or stages of TDLU involution. 
TDLU involution may occur in women by either reducing the number of TDLUs or reducing 
the number of acini within the TDLUs, both resulting in decreased overall epithelial content 
in breast. Finally, because women must have had at least one observable TDLU to be 
included in the analysis for acini count/TDLU, we may have had limited statistical power to 
detect some modest associations between serum EMs and acini count/TDLU.
We acknowledge several limitations of this study. Because we performed multiple tests with 
44 different individual EMs, pathway groups, and ratios, some of the significant findings we 
observed could be due to chance. The majority of our findings did not remain statistically 
significant after the adjustment for multiple testing, potentially due to limited sample size 
and the possible modest effects of EMs on TDLU involution. However, given the 
exploratory nature of the study, this study serves as a hypothesisgenerating analysis that may 
provide a basis for future studies. In stratified analyses, we had a limited sample size in each 
subgroup and thus we were not able to adjust for potential confounders in these models other 
than age. However, in our overall analyses the age-adjusted and the multivariable-adjusted 
results were very similar.
Despite the limitations, this study has important strengths. We used reproducible, 
standardized measures of TDLU involution. Use of the LC/MS-MS assay also allowed us to 
comprehensively measure 15 individual EMs with high sensitivity, specificity, and reliability 
[30,25], even for the lower levels of estradiol characteristic of postmenopausal women [42–
44]. In summary, we observed that serum levels of estradiol and certain individual EMs were 
generally associated with higher TDLU count among both pre- and post-menopausal women 
with BBD. These findings were independent of circulating unconjugated estradiol, 
suggesting a possible role of EMs in influencing TDLU involution. As both estrogen 
metabolism and TDLU involution are potentially modifiable breast cancer risk factors, this 
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study provides impetus for further research incorporating these metrics as a means of 
refining risk assessment for breast cancer.
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Table 1
Characteristics of the study population in the NCI Breast Radiology Evaluation and Study of Tissues 
(BREAST) Stamp Project, stratified by menopausal status
Premenopausal
(N=94)
Postmenopausal
(N=92)
Mean (SD)
Age at biopsy, years 45.8 (3.6) 57.2 (4.1)
Body mass index, kg/m2 25.2 (5.6) 26.9 (5.9)
Percentage of fat on the H&E-stained breast biopsy slide 38.7 (27.6) 42.9 (26.3)
Volume mammographic density a
  Percent fibroglandular volume, % 49.3 (23.2) 32.2 (17.9)
  Absolute fibroglandular volume, cm3 211.1 (105.8) 188.3 (97.2)
N (%)
White, non-Hispanic race 87 (92.6) 85 (92.4)
Age at menarche
  ≤12 years 27 (28.7) 37 (40.2)
  13 years 43 (45.7) 29 (31.5)
  ≥ 14 years 24 (25.5) 26 (28.3)
Menstrual cycle phase (among premenopausal women)
  Follicular 31 (33.0)
  Periovulatory 25 (26.6)
  Luteal 38 (40.4)
Age at menopause (among postmenopausal women)
  <45 years 17 (20.7)
  45–49 years 22 (26.8)
  50–54 years 37 (45.1)
  ≥ 55 years 6 (7.3)
Parity
  Nulliparous 24 (25.5) 20 (21.7)
  Parous, age at first birth <30 years 45 (47.9) 56 (60.9)
  Parous, age at first birth ≥30 years 25 (26.6) 16 (17.4)
First-degree family history of breast cancer 23 (24.5) 25 (27.2)
Smoking
  Never 56 (59.6) 38 (41.3)
  Former 31 (33.0) 42 (45.7)
  Current 7 (7.4) 11 (12.0)
Former use of oral contraceptives 82 (87.2) 77 (83.7)
Type of biopsy
  Needle core (ultrasound) 53 (56.4) 40 (43.5)
  Vacuum assisted (stereotactic) 41 (43.6) 52 (56.5)
Pathologic diagnosis
  Benign 36 (38.3) 29 (31.5)
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Premenopausal
(N=94)
Postmenopausal
(N=92)
  Proliferative 44 (46.8) 31 (33.7)
  Proliferative with atypia 5 (5.3) 10 (10.9)
  Carcinoma (in situ, invasive) 9 (9.6) 22 (23.9)
TDLU involution measures
  ≥1 TDLU observed, N (%) 75 (79.8) 59 (64.1)
  TDLU count per 100 mm2 nonfat area [median (IQR)] b 41.9 (68.8) 22.9 (33.0)
  Median acini count per TDLU [median (IQR)] 15.8 (9.0) 8.0 (6.5)
a
Dense volume of the ipsilateral breast
bValues were estimated among women with at least one TDLU on the H&E slide
Abbreviations : H&E=hematoxylin and eosin, IQR = interquartile range, SD=standard deviation, TDLU=terminal duct lobular unit
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